Crinetics Pharmaceuticals (CRNX) Assets Average (2018 - 2026)

Crinetics Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 9.6% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 9.6% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 23.72% from the prior year.
• Assets Average advanced to $1.3 billion in Q1 2026 per CRNX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.4 billion in Q1 2025 and bottomed at $303.6 million in Q2 2023.
• The 5-year median for Assets Average is $806.8 million (2024), against an average of $794.8 million.
• Across the five-year window, Assets Average fell 19.57% in 2023 and soared 215.13% in 2024, its largest moves.
• Year by year, Assets Average stood at $368.5 million in 2022, then soared by 73.24% to $638.4 million in 2023, then soared by 85.76% to $1.2 billion in 2024, then decreased by 2.09% to $1.2 billion in 2025, then rose by 8.84% to $1.3 billion in 2026.
• Per Business Quant, the three latest CRNX Assets Average figures stand at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).